99.34% High Purity Anti Estrogen Steroids , Raloxifene Hydrochloride HCL Powder CAS 82640-04-8

Basic Information
Place of Origin: CHINA
Brand Name: GSP
Certification: GMP , ISO 9001:2008
Model Number: CAS: 82640-04-8
Minimum Order Quantity: 10g
Price: Contact Us
Packaging Details: Stealth And Discreet Packaging
Delivery Time: Within 7 Working Days
Payment Terms: Bank Transfer - Bitcoin - Western Union - MoneyGram
Supply Ability: 500 KG/Month
Other Name: Raloxifene ; Raloxifene HCL MF: C28H28ClNO4S
MW: 510.04 Melting Point: 250-253°C
Storage Temp: -20°C Freezer Solubility DMSO: 28 Mg/ML, Soluble
Appearance: Light Yellow Solid
High Light:

anti estrogen supplements


anti estrogen drugs


99.34% Anti-Estrogen Raloxifene Hydrochloride Powder / Raloxifene HCL Powder




Raloxifen hydrochloride, a second-generation Selective Estrogen Receptor Modulator (SERM) in


the Raloxifene hydrochloride benzothiophene family. On September 13, 2007, the U. S. Food and


Drug Administration approved Evista for reduction in the risk of invasive breast cancer in


postmenopausal women with and Raloxifene hydrochloride without osteoporosis. It has also been


approved as a potent stand-alone osteoporosis treatment.


Raloxifene hydrochlorideMay prevent or treat corticosteroid-induced bone loss .American


College of Rheumatology states that raloxifene can be offered to selected postmenopausal


corticosteroid-treated women who refuse hormone replacement therapy or other Raloxifene


hydrochloride antiresorptive agents or in whom such therapies are contraindicated.

Reduction in the incidence Raloxifene hydrochloride of invasive breast cancer in postmenopausal


women with osteoporosis.


Reduction in the incidence of invasive breast cancer in postmenopausal women at high risk for


developing the disease. Effect comparable to that of tamoxifen in reducing the risk of invasive


breast cancer (STAR trial). No effect on the risk of lobular carcinoma in situ or ductal carcinoma


in situ (STAR trial). Effect on breast cancer incidence in women with Raloxifene hydrochloride


BRCA1 or BRCA2 genetic mutations not established.




1.Amino acid, nutrient

2.Labeled Raloxifene, intended for use as an internal standard for the quantification of Raloxifene


by GC- or LC-mass spectrometry.

3.A nonsteroidal, selective estrogen receptor modulator (SERM). Antiosteoporotic.



Side Effects:

Raloxifene may infrequently cause serious blood clots to form in the legs, lungs, or eyes. Other


reactions experienced include leg swelling/pain, trouble breathing, chest pain, vision changes.


Raloxifene is a teratogenic drug, which can cause developmental abnormalities such as birth





99.34% High Purity Anti Estrogen Steroids , Raloxifene Hydrochloride HCL Powder CAS 82640-04-8 0




Anti-Estrogen Series


Tamoxifen Citrate (Nolvadex)


Dutasteride (Avodart)


Clomifene Citrate (Clomid)


Finasteride (Proscar)


Letrozole (Femara)


Formestane (Lentaron)


Toremifene Citrate (Fareston)


Cabergoline (Caber)


Exemestane (Aromasin)


Raloxifene Hydrochloride


Anastrozole (Arimidex)





Any needs, please contact us


Email: giantsteroidsource@protonmail.com


Contact Details

Phone Number : +8615827096298

WhatsApp : +https://api.whatsapp.com/send?phone=8613657291547